Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine

Biological Psychiatry

Volumn 81, Issue 10, 2017, Pages 886-897

  Lener, Marc S ^a   Niciu, Mark J ^a   Ballard, Elizabeth D ^a   Park, Minkyung ^a   Park, Lawrence T ^a   Nugent, Allison C ^a   Zarate, Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Bipolar disorder; Glutamate; Ketamine; Major depressive disorder; Mood disorder; NMDA receptor antagonist

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMIC ACID; KETAMINE; ANTIDEPRESSANT AGENT;

ANTIDEPRESSANT ACTIVITY; GABAERGIC TRANSMISSION; GLUTAMATERGIC NEUROTRANSMISSION; HUMAN; MAJOR DEPRESSION; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ANIMAL; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; KETAMINE;

EID: 84978796197     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2016.05.005     Document Type: Review

References (122)

1. 1 Trullas, R., Skolnick, P., Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185 (1990), 1–10.
2. 2 Maeng, S., Zarate, C.A. Jr, Du, J., Schloesser, R.J., McCammon, J., Chen, G., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63 (2008), 349–352.
3. 3 Musazzi, L., Racagni, G., Popoli, M., Stress, glucocorticoids and glutamate release: Effects of antidepressant drugs. Neurochem Int 59 (2011), 138–149.
4. 4 Skolnick, P., Layer, R.T., Popik, P., Nowak, G., Paul, I.A., Trullas, R., Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: Implications for the pharmacotherapy of depression. Pharmacopsychiatry 29 (1996), 23–26.
5. 5 Nowak, G., Trullas, R., Layer, R.T., Skolnick, P., Paul, I.A., Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 265 (1993), 1380–1386.
6. 6 Sanacora, G., Treccani, G., Popoli, M., Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 62 (2012), 63–77.
7. 7 Kohrs, R., Durieux, M.E., Ketamine: Teaching an old drug new tricks. Anesth Analg 87 (1998), 1186–1193.
8. 8 Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lancon, C., Brittner, M., et al. Ketamine administration in depressive disorders: A systematic review and meta-analysis. Psychopharmacology (Berl) 231 (2014), 3663–3676.
9. 9 Newport, D.J., Carpenter, L.L., McDonald, W.M., Potash, J.B., Tohen, M., Nemeroff, C.B., et al. Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression. Am J Psychiatry 172 (2015), 950–966.
10. 10 Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47 (2000), 351–354.
11. 11 Zarate, C.A. Jr, Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63 (2006), 856–864.
12. 12 Mathew, S.J., Murrough, J.W., aan het Rot, M., Collins, K.A., Reich, D.L., Charney, D.S., Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 13 (2010), 71–82.
13. 13 Murrough, J.W., Iosifescu, D.V., Chang, L.C., Al Jurdi, R.K., Green, C.E., Perez, A.M., et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry 170 (2013), 1134–1142.
14. 14 Messer, M., Haller, I.V., Larson, P., Pattison-Crisostomo, J., Gessert, C.E., The use of a series of ketamine infusions in two patients with treatment-resistant depression. J Neuropsychiatry Clin Neurosci 22 (2010), 442–444.
15. 15 Niciu, M.J., Ionescu, D.F., Richards, E.M., Zarate, C.A. Jr, Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna) 121 (2014), 907–924.
16. 16 Bak, L.K., Schousboe, A., Waagepetersen, H.S., The glutamate/GABA-glutamine cycle: Aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem 98 (2006), 641–653.
17. 17 Lener, M.S., Iosifescu, D.V., In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: A review of the literature. Ann N Y Acad Sci 1344 (2015), 50–65.
18. 18 Yuksel, C., Ongur, D., Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 68 (2010), 785–794.
19. 19 Arnone, D., Mumuni, A.N., Jauhar, S., Condon, B., Cavanagh, J., Indirect evidence of selective glial involvement in glutamate-based mechanisms of mood regulation in depression: Meta-analysis of absolute prefrontal neuro-metabolic concentrations. Eur Neuropsychopharmacol 25 (2015), 1109–1117.
20. 20 Chitty, K.M., Lagopoulos, J., Lee, R.S., Hickie, I.B., Hermens, D.F., A systematic review and meta-analysis of proton magnetic resonance spectroscopy and mismatch negativity in bipolar disorder. Eur Neuropsychopharmacol 23 (2013), 1348–1363.
21. 21 Ehrlich, A., Schubert, F., Pehrs, C., Gallinat, J., Alterations of cerebral glutamate in the euthymic state of patients with bipolar disorder. Psychiatry Res 233 (2015), 73–80.
22. 22 Yildiz-Yesiloglu, A., Ankerst, D.P., Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: A meta-analysis. Psychiatry Res 147 (2006), 1–25.
23. 23 Hasler, G., van der Veen, J.W., Tumonis, T., Meyers, N., Shen, J., Drevets, W.C., Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 64 (2007), 193–200.
24. 24 Auer, D.P., Putz, B., Kraft, E., Lipinski, B., Schill, J., Holsboer, F., Reduced glutamate in the anterior cingulate cortex in depression: An in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 47 (2000), 305–313.
25. 25 Sanacora, G., Gueorguieva, R., Epperson, C.N., Wu, Y.T., Appel, M., Rothman, D.L., et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61 (2004), 705–713.
26. 26 de Diego-Adelino, J., Portella, M.J., Gomez-Anson, B., Lopez-Moruelo, O., Serra-Blasco, M., Vives, Y., et al. Hippocampal abnormalities of glutamate/glutamine, N-acetylaspartate and choline in patients with depression are related to past illness burden. J Psychiatry Neurosci 38 (2013), 107–116.
27. 27 Abdallah, C.G., Jiang, L., De Feyter, H.M., Fasula, M., Krystal, J.H., Rothman, D.L., et al. Glutamate metabolism in major depressive disorder. Am J Psychiatry 171 (2014), 1320–1327.
28. 28 Senaratne, R., Milne, A.M., MacQueen, G.M., Hall, G.B., Increased choline-containing compounds in the orbitofrontal cortex and hippocampus in euthymic patients with bipolar disorder: A proton magnetic resonance spectroscopy study. Psychiatry Res 172 (2009), 205–209.
29. 29 Port, J.D., Unal, S.S., Mrazek, D.A., Marcus, S.M., Metabolic alterations in medication-free patients with bipolar disorder: A 3T CSF-corrected magnetic resonance spectroscopic imaging study. Psychiatry Res 162 (2008), 113–121.
30. 30 Kaufman, R.E., Ostacher, M.J., Marks, E.H., Simon, N.M., Sachs, G.S., Jensen, J.E., et al. Brain GABA levels in patients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 33 (2009), 427–434.
31. 31 Frye, M.A., Watzl, J., Banakar, S., O'Neill, J., Mintz, J., Davanzo, P., et al. Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacology 32 (2007), 2490–2499.
32. 32 Gigante, A.D., Bond, D.J., Lafer, B., Lam, R.W., Young, L.T., Yatham, L.N., Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: A meta-analysis. Bipolar Disord 14 (2012), 478–487.
33. 33 Dager, S.R., Friedman, S.D., Parow, A., Demopulos, C., Stoll, A.L., Lyoo, I.K., et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 61 (2004), 450–458.
34. 34 Haroon, E., Fleischer, C.C., Felger, J.C., Chen, X., Woolwine, B.J., Patel, T., et al. Conceptual convergence: Increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Mol Psychiatry 21 (2016), 1351–1357.
35. 35 Malhi, G.S., Byrow, Y., Fritz, K., Das, P., Baune, B.T., Porter, R.J., et al. Mood disorders: Neurocognitive models. Bipolar Disord 17:suppl 2 (2015), 3–20.
36. 36 Fears, S.C., Service, S.K., Kremeyer, B., Araya, C., Araya, X., Bejarano, J., et al. Multisystem component phenotypes of bipolar disorder for genetic investigations of extended pedigrees. JAMA Psychiatry 71 (2014), 375–387.
37. 37 Price, R.B., Shungu, D.C., Mao, X., Nestadt, P., Kelly, C., Collins, K.A., et al. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: Relationship to treatment resistance in major depressive disorder. Biol Psychiatry 65 (2009), 792–800.
38. 38 Sanacora, G., Zarate, C.A., Krystal, J.H., Manji, H.K., Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7 (2008), 426–437.
39. 39 Salvadore, G., Zarate, C.A. Jr, Magnetic resonance spectroscopy studies of the glutamatergic system in mood disorders: A pathway to diagnosis, novel therapeutics, and personalized medicine?. Biol Psychiatry 68 (2010), 780–782.
40. 40 DeLorenzo, C., Sovago, J., Gardus, J., Xu, J., Yang, J., Behrje, R., et al. Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [(11)C]ABP688. Transl Psychiatry, 5, 2015, e693.
41. 41 Deschwanden, A., Karolewicz, B., Feyissa, A.M., Treyer, V., Ametamey, S.M., Johayem, A., et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry 168 (2011), 727–734.
42. 42 Li, X., Need, A.B., Baez, M., Witkin, J.M., Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther 319 (2006), 254–259.
43. 43 Palucha, A., Branski, P., Szewczyk, B., Wieronska, J.M., Klak, K., Pilc, A., Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav 81 (2005), 901–906.
44. 44 Tatarczynska, E., Klodzinska, A., Chojnacka-Wojcik, E., Palucha, A., Gasparini, F., Kuhn, R., et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 132 (2001), 1423–1430.
45. 45 Golla, S.S., Klein, P.J., Bakker, J., Schuit, R.C., Christiaans, J.A., van Geest, L., et al. Preclinical evaluation of [(18)F]PK-209, a new PET ligand for imaging the ion-channel site of NMDA receptors. Nucl Med Biol 42 (2015), 205–212.
46. 46 Sanacora, G., Mason, G.F., Rothman, D.L., Behar, K.L., Hyder, F., Petroff, O.A., et al. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 56 (1999), 1043–1047.
47. 47 Hasler, G., Neumeister, A., van der Veen, J.W., Tumonis, T., Bain, E.E., Shen, J., et al. Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy. Biol Psychiatry 58 (2005), 969–973.
48. 48 Bhagwagar, Z., Wylezinska, M., Jezzard, P., Evans, J., Boorman, E., Matthews, P.M., et al. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 11 (2008), 255–260.
49. 49 Brady, R.O. Jr, McCarthy, J.M., Prescot, A.P., Jensen, J.E., Cooper, A.J., Cohen, B.M., et al. Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder. Bipolar Disord 15 (2013), 434–439.
50. 50 Soeiro-de-Souza, M.G., Henning, A., Machado-Vieira, R., Moreno, R.A., Pastorello, B.F., da Costa Leite, C., et al. Anterior cingulate Glutamate-Glutamine cycle metabolites are altered in euthymic bipolar I disorder. Eur Neuropsychopharmacol 25 (2015), 2221–2229.
51. 51 Krystal, J.H., Sanacora, G., Blumberg, H., Anand, A., Charney, D.S., Marek, G., et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 7:suppl 1 (2002), S71–S80.
52. 52 Vigo, D.V., Baldessarini, R.J., Anticonvulsants in the treatment of major depressive disorder: An overview. Harv Rev Psychiatry 17 (2009), 231–241.
53. 53 Bowden, C.L., Calabrese, J.R., McElroy, S.L., Gyulai, L., Wassef, A., Petty, F., et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 57 (2000), 481–489.
54. 54 Kinon, B.J., Millen, B.A., Zhang, L., McKinzie, D.L., Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry 78 (2015), 754–762.
55. 55 Lally, N., An, L., Banerjee, D., Niciu, M.J., Luckenbaugh, D.A., Richards, E.M., et al. Reliability of 7T (1) H-MRS measured human prefrontal cortex glutamate, glutamine, and glutathione signals using an adapted echo time optimized PRESS sequence: A between- and within-sessions investigation. J Magn Reson Imaging 43 (2016), 88–98.
56. 56 Insel, T.R., The NIMH Research Domain Criteria (RDoC) Project: Precision medicine for psychiatry. Am J Psychiatry 171 (2014), 395–397.
57. 57 Zhang, L.I., Poo, M.M., Electrical activity and development of neural circuits. Nat Neurosci 4:suppl (2001), 1207–1214.
58. 58 Cohen, D., Cuffin, B.N., Demonstration of useful differences between magnetoencephalogram and electroencephalogram. Electroencephalogr Clin Neurophysiol 56 (1983), 38–51.
59. 59 Reite, M., Teale, P., Rojas, D.C., Magnetoencephalography: Applications in psychiatry. Biol Psychiatry 45 (1999), 1553–1563.
60. 60 Atasoy, S., Donnelly, I., Pearson, J., Human brain networks function in connectome-specific harmonic waves. Nat Commun, 7, 2016, 10340.
61. 61 Buzsaki, G., Draguhn, A., Neuronal oscillations in cortical networks. Science 304 (2004), 1926–1929.
62. 62 Greicius, M.D., Flores, B.H., Menon, V., Glover, G.H., Solvason, H.B., Kenna, H., et al. Resting-state functional connectivity in major depression: Abnormally increased contributions from subgenual cingulate cortex and thalamus. Biol Psychiatry 62 (2007), 429–437.
63. 63 Kaiser, R.H., Andrews-Hanna, J.R., Wager, T.D., Pizzagalli, D.A., Large-scale network dysfunction in major depressive disorder: A meta-analysis of resting-state functional connectivity. JAMA. Psychiatry 72 (2015), 603–611.
64. 64 Alcaro, A., Panksepp, J., Witczak, J., Hayes, D.J., Northoff, G., Is subcortical-cortical midline activity in depression mediated by glutamate and GABA? A cross-species translational approach. Neurosci Biobehav Rev 34 (2010), 592–605.
65. 65 Price, J.L., Drevets, W.C., Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci 16 (2012), 61–71.
66. 66 Gabbay, V., Mao, X., Klein, R.G., Ely, B.A., Babb, J.S., Panzer, A.M., et al. Anterior cingulate cortex gamma-aminobutyric acid in depressed adolescents: Relationship to anhedonia. Arch Gen Psychiatry 69 (2012), 139–149.
67. 67 Vargas, C., Lopez-Jaramillo, C., Vieta, E., A systematic literature review of resting state network-Functional MRI in bipolar disorder. J Affect Disord 150 (2013), 727–735.
68. 68 He, H., Yu, Q., Du, Y., Vergara, V., Victor, T.A., Drevets, W.C., et al. Resting-state functional network connectivity in prefrontal regions differs between unmedicated patients with bipolar and major depressive disorders. J Affect Disord 190 (2016), 483–493.
69. 69 Rive, M.M., Mocking, R.J., Koeter, M.W., van Wingen, G., de Wit, S.J., van den Heuvel, O.A., et al. State-dependent differences in emotion regulation between unmedicated bipolar disorder and major depressive disorder. JAMA. Psychiatry 72 (2015), 687–696.
70. 70 Brookes, M.J., Woolrich, M., Luckhoo, H., Price, D., Hale, J.R., Stephenson, M.C., et al. Investigating the electrophysiological basis of resting state networks using magnetoencephalography. Proc Natl Acad Sci U S A 108 (2011), 16783–16788.
71. 71 Brookes, M.J., Liddle, E.B., Hale, J.R., Woolrich, M.W., Luckhoo, H., Liddle, P.F., et al. Task induced modulation of neural oscillations in electrophysiological brain networks. Neuroimage 63 (2012), 1918–1930.
72. 72 Hasler, G., Northoff, G., Discovering imaging endophenotypes for major depression. Mol Psychiatry 16 (2011), 604–619.
73. 73 Nugent, A.C., Robinson, S.E., Coppola, R., Furey, M.L., Zarate, C.A. Jr, Group differences in MEG-ICA derived resting state networks: Application to major depressive disorder. Neuroimage 118 (2015), 1–12.
74. 74 Pizzagalli, D.A., Frontocingulate dysfunction in depression: Toward biomarkers of treatment response. Neuropsychopharmacology 36 (2011), 183–206.
75. 75 Drevets, W.C., Savitz, J., Trimble, M., The subgenual anterior cingulate cortex in mood disorders. CNS Spectr 13 (2008), 663–681.
76. 76 Duncan, N.W., Wiebking, C., Tiret, B., Marjanska, M., Hayes, D.J., Lyttleton, O., et al. Glutamate concentration in the medial prefrontal cortex predicts resting-state cortical-subcortical functional connectivity in humans. PLoS One, 8, 2013, e60312.
77. 77 Horn, D.I., Yu, C., Steiner, J., Buchmann, J., Kaufmann, J., Osoba, A., et al. Glutamatergic and resting-state functional connectivity correlates of severity in major depression–The role of pregenual anterior cingulate cortex and anterior insula. Front Syst Neurosci, 4, 2010, 33.
78. 78 Walter, M., Henning, A., Grimm, S., Schulte, R.F., Beck, J., Dydak, U., et al. The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch Gen Psychiatry 66 (2009), 478–486.
79. 79 Hutchison, R.M., Womelsdorf, T., Allen, E.A., Bandettini, P.A., Calhoun, V.D., Corbetta, M., et al. Dynamic functional connectivity: Promise, issues, and interpretations. Neuroimage 80 (2013), 360–378.
80. 80 Harraz, M.M., Tyagi, R., Cortes, P., Snyder, S.H., Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation. Mol Psychiatry 3 (2016), 313–319.
81. 81 Li, N., Liu, R.J., Dwyer, J.M., Banasr, M., Lee, B., Son, H., et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69 (2011), 754–761.
82. 82 Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329 (2010), 959–964.
83. 83 Homayoun, H., Moghaddam, B., NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27 (2007), 11496–11500.
84. 84 Niciu, M.J., Mathews, D.C., Nugent, A.C., Ionescu, D.F., Furey, M.L., Richards, E.M., et al. Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. Depress Anxiety 31 (2014), 297–307.
85. 85 Sanacora, G., Smith, M.A., Pathak, S., Su, H.L., Boeijinga, P.H., McCarthy, D.J., et al. Lanicemine: A low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 19 (2014), 978–985.
86. 86 Park, M., Niciu, M.J., Zarate, C.A. Jr, Novel glutamatergic treatments for severe mood disorders. Curr Behav Neurosci Rep 2 (2015), 198–208.
87. 87 Rowland, L.M., Bustillo, J.R., Mullins, P.G., Jung, R.E., Lenroot, R., Landgraf, E., et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: A 4-T proton MRS study. Am J Psychiatry 162 (2005), 394–396.
88. 88 Taylor, M.J., Tiangga, E.R., Mhuircheartaigh, R.N., Cowen, P.J., Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: A proton magnetic resonance spectroscopy study. J Psychopharmacol 26 (2012), 733–737.
89. 89 Stone, J.M., Dietrich, C., Edden, R., Mehta, M.A., De Simoni, S., Reed, L.J., et al. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: Relationship to ketamine-induced psychopathology. Mol Psychiatry 17 (2012), 664–665.
90. 90 DeLorenzo, C., DellaGioia, N., Bloch, M., Sanacora, G., Nabulsi, N., Abdallah, C., et al. In vivo ketamine-induced changes in [(11)C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biol Psychiatry 77 (2015), 266–275.
91. 91 Fuxe, K., Borroto-Escuela, D.O., Basimglurant for treatment of major depressive disorder: A novel negative allosteric modulator of metabotropic glutamate receptor 5. Expert Opin Investig Drugs 24 (2015), 1247–1260.
92. 92 Salvadore, G., van der Veen, J.W., Zhang, Y., Marenco, S., Machado-Vieira, R., Baumann, J., et al. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol 15 (2012), 1063–1072.
93. 93 Milak, M.S., Proper, C.J., Mulhern, S.T., Parter, A.L., Kegeles, L.S., Ogden, R.T., et al. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol Psychiatry 21 (2016), 320–327.
94. 94 Valentine, G.W., Mason, G.F., Gomez, R., Fasula, M., Watzl, J., Pittman, B., et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 191 (2011), 122–127.
95. 95 Grimm, O., Gass, N., Weber-Fahr, W., Sartorius, A., Schenker, E., Spedding, M., et al. Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats. Psychopharmacology (Berl) 232 (2015), 4231–4241.
96. 96 Scheidegger, M., Walter, M., Lehmann, M., Metzger, C., Grimm, S., Boeker, H., et al. Ketamine decreases resting state functional network connectivity in healthy subjects: Implications for antidepressant drug action. PLoS One, 7, 2012, e44799.
97. 97 Lally, N., Nugent, A.C., Luckenbaugh, D.A., Niciu, M.J., Roiser, J.P., Zarate, C.A. Jr, Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol 29 (2015), 596–607.
98. 98 Carlson, P.J., Diazgranados, N., Nugent, A.C., Ibrahim, L., Luckenbaugh, D.A., Brutsche, N., et al. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: A preliminary positron emission tomography study. Biol Psychiatry 73 (2013), 1213–1221.
99. 99 Li, C.T., Chen, M.H., Lin, W.C., Hong, C.J., Yang, B.H., Liu, R.S., et al. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study. Hum Brain Mapp 37 (2016), 1080–1090.
100. 100 Lally, N., Nugent, A.C., Luckenbaugh, D.A., Ameli, R., Roiser, J.P., Zarate, C.A., Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry, 4, 2014, e469.
101. 101 Nugent, A.C., Diazgranados, N., Carlson, P.J., Ibrahim, L., Luckenbaugh, D.A., Brutsche, N., et al. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord 16 (2014), 119–128.
102. 102 Carlen, M., Meletis, K., Siegle, J.H., Cardin, J.A., Futai, K., Vierling-Claassen, D., et al. A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol Psychiatry 17 (2012), 537–548.
103. 103 Grunze, H.C., Rainnie, D.G., Hasselmo, M.E., Barkai, E., Hearn, E.F., McCarley, R.W., et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 16 (1996), 2034–2043.
104. 104 Pinault, D., N-methyl d-aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex. Biol Psychiatry 63 (2008), 730–735.
105. 105 Wood, J., Kim, Y., Moghaddam, B., Disruption of prefrontal cortex large scale neuronal activity by different classes of psychotomimetic drugs. J Neurosci 32 (2012), 3022–3031.
106. 106 Godsil, B.P., Kiss, J.P., Spedding, M., Jay, T.M., The hippocampal-prefrontal pathway: The weak link in psychiatric disorders?. Eur Neuropsychopharmacol 23 (2013), 1165–1181.
107. 107 Shaw, A.D., Saxena NJackson, L.E., Hall, J.E., Singh, K.D., Muthukumaraswamy, S.D., Ketamine amplifies induced gamma frequency oscillations in the human cerebral cortex. Eur Neuropsychopharmacol 25 (2015), 1136–1146.
108. 108 Gass, N., Schwarz, A.J., Sartorius, A., Schenker, E., Risterucci, C., Spedding, M., et al. Sub-anesthetic ketamine modulates intrinsic BOLD connectivity within the hippocampal-prefrontal circuit in the rat. Neuropsychopharmacology 39 (2014), 895–906.
109. 109 Tagliazucchi, E., von Wegner, F., Morzelewski, A., Brodbeck, V., Laufs, H., Dynamic BOLD functional connectivity in humans and its electrophysiological correlates. Front Hum Neurosci, 6, 2012, 339.
110. 110 Kamiyama, H., Matsumoto, M., Otani, S., Kimura, S.I., Shimamura, K.I., Ishikawa, S., et al. Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medial prefrontal cortex pathway. Neuroscience 177 (2011), 159–169.
111. 111 Kapogiannis, D., Reiter, D.A., Willette, A.A., Mattson, M.P., Posteromedial cortex glutamate and GABA predict intrinsic functional connectivity of the default mode network. Neuroimage 64 (2013), 112–119.
112. 112 Muthukumaraswamy, S.D., Shaw, A.D., Jackson, L.E., Hall, J., Moran, R., Saxena, N., Evidence that subanesthetic doses of ketamine cause sustained disruptions of NMDA and AMPA-mediated frontoparietal connectivity in humans. J Neurosci 35 (2015), 11694–11706.
113. 113 Wise, R.G., Tracey, I., The role of fMRI in drug discovery. J Magn Reson Imaging 23 (2006), 862–876.
114. 114 De Simoni, S., Schwarz, A.J., O'Daly, O.G., Marquand, A.F., Brittain, C., Gonzales, C., et al. Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. Neuroimage 64 (2013), 75–90.
115. 115 Doyle, O.M., De Simoni, S., Schwarz, A.J., Brittain, C., O'Daly, O.G., Williams, S.C., et al. Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: A validation using antipsychotic and glutamatergic agents. J Pharmacol Exp Ther 345 (2013), 151–160.
116. 116 Phillips, M.L., Chase, H.W., Sheline, Y.I., Etkin, A., Almeida, J.R., Deckersbach, T., et al. Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: Neuroimaging approaches. Am J Psychiatry 172 (2015), 124–138.
117. 117 Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475 (2011), 91–95.
118. 118 Machado-Vieira, R., Yuan, P., Brutsche, N., DiazGranados, N., Luckenbaugh, D., Manji, H.K., et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry 70 (2009), 1662–1666.
119. 119 Davidson, R.J., Lewis, D.A., Alloy, L.B., Amaral, D.G., Bush, G., Cohen, J.D., et al. Neural and behavioral substrates of mood and mood regulation. Biol Psychiatry 52 (2002), 478–502.
120. 120 Schmidt, H.D., Shelton, R.C., Duman, R.S., Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 36 (2011), 2375–2394.
121. 121 Mayberg, H.S., Neuroimaging and psychiatry: The long road from bench to bedside. Hastings Cent Rep Spec No, 2014, S31–S36.
122. 122 Nugent, A.C., Martinez, A., D'Alfonso, A., Zarate, C.A., Theodore, W.H., The relationship between glucose metabolism, resting-state fMRI BOLD signal, and GABAA-binding potential: A preliminary study in healthy subjects and those with temporal lobe epilepsy. J Cereb Blood Flow Metab 35 (2015), 583–591.